Medpace could benefit as more drugmakers hand off clinical trial work and as newer, more flexible trial designs become the norm. The catch is that it relies on a small group of customers and faces rising rule-making and fast-moving tech changes that could squeeze future growth.Read more
Medpace looks like it’s benefiting from a rush of fast-moving work right now, but that boost may fade as projects and client budgets shift. If smaller biotech customers pull back or costs keep climbing, today’s strong results could prove less stable than they seem.Read more
Medpace’s recent growth may look stronger than it really is because it’s being boosted by certain types of clinical trials that bring in lots of billable costs but don’t help profits as much. At the same time, a thinner pipeline of future work, tougher competition, and rising staffing costs could pressure results—unless industry demand and Medpace’s execution keep the momentum going.Read more
No trending discussion available.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
